Related references
Note: Only part of the references are listed.Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311)
Robert L. Ferris et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Implications and Emerging Therapeutic Avenues of Inflammatory Response in HPV plus Head and Neck Squamous Cell Carcinoma
Lucio Roberto Cancado Castellano et al.
CANCERS (2022)
A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC)
J. Chandra et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Defining HPV-specific B cell responses in patients with head and neck cancer
Andreas Wieland et al.
NATURE (2021)
Characteristics of B lymphocyte infiltration in HPV+ head and neck squamous cell carcinoma
Siwei Zhang et al.
CANCER SCIENCE (2021)
TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers
Nisha B. Nagarsheth et al.
NATURE MEDICINE (2021)
Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells
Rebekka Duhen et al.
NATURE COMMUNICATIONS (2021)
The Role of B Cells in Head and Neck Cancer
Niki Gavrielatou et al.
CANCERS (2021)
Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer
Supitcha Kamolratanakul et al.
VACCINES (2021)
Head and neck cancer
Mayur D. Mody et al.
LANCET (2021)
Functional HPV-specific PD-1+ stem-like CD8 T cells in head and neck cancer
Christiane S. Eberhardt et al.
NATURE (2021)
A Contemporary Systematic Review on Repartition of HPV-Positivity in Oropharyngeal Cancer Worldwide
Amanda F. Carlander et al.
VIRUSES-BASEL (2021)
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open -label phase III study
R. L. Ferris et al.
ANNALS OF ONCOLOGY (2020)
B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade
Sangwoo S. Kim et al.
CLINICAL CANCER RESEARCH (2020)
Prognostic value of novel immune-related genomic biomarkers identified in head and neck squamous cell carcinoma
Yao Yao et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
HPV-related squamous cell carcinoma of oropharynx: a review
Siavash Rahimi
JOURNAL OF CLINICAL PATHOLOGY (2020)
Safety and efficacy of MEDI0457 plus durvalumab in patients (pts) with human papillomavirus-associated recurrent/metastatic head and neck squamous cell carcinoma (HPV plus R/M HNSCC)
C. Aggarwal et al.
ANNALS OF ONCOLOGY (2020)
Turning the corner on therapeutic cancer vaccines
Robert E. Hollingsworth et al.
NPJ VACCINES (2019)
Prevalence of Oral HPV Infection in Unvaccinated Men and Women in the United States, 2009-2016
Anil K. Chaturvedi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
T-Cell Receptor Gene Therapy for Human Papillomavirus-Associated Epithelial Cancers: A First-in-Human, Phase I/II Study
Stacey L. Doran et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The effects and safety of PD-1/PD-L1 inhibitors on head and neck cancer: A systematic review and meta-analysis
Bi-Cheng Wang et al.
CANCER MEDICINE (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer A Phase 2 Clinical Trial
Erminia Massarelli et al.
JAMA ONCOLOGY (2019)
Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8+ T cells
Kamila Hladikova et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
T cell receptor-engineered T cells for leukemia immunotherapy
Yikai Zhang et al.
CANCER CELL INTERNATIONAL (2019)
Human Papillomavirus (HPV) Vaccine Effectiveness and Potential Herd Immunity for Reducing Oncogenic Oropharyngeal HPV-16 Prevalence in the United Kingdom: A Cross-sectional Study
Hisham Mehanna et al.
CLINICAL INFECTIOUS DISEASES (2019)
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
Dan P. Zandberg et al.
EUROPEAN JOURNAL OF CANCER (2019)
Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy
Imran Siddiqui et al.
IMMUNITY (2019)
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E. W. Cohen et al.
LANCET (2019)
Risk of Oral Human Papillomavirus Infection Among Sexually Active Female Adolescents Receiving the Quadrivalent Vaccine
Nicolas F. Schlecht et al.
JAMA NETWORK OPEN (2019)
Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer
Charu Aggarwal et al.
CLINICAL CANCER RESEARCH (2019)
A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298
Timothy J. Wilkin et al.
CLINICAL INFECTIOUS DISEASES (2018)
Effect of Prophylactic Human Papillomavirus (HPV) Vaccination on Oral HPV Infections Among Young Adults in the United States
Anil K. Chaturvedi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
Robert L. Ferris et al.
ORAL ONCOLOGY (2018)
Immunotherapy for Head and Neck Squamous Cell Carcinoma
Jessica Moskovitz et al.
CURRENT ONCOLOGY REPORTS (2018)
Prognostic Significance of PD-L1+ and CD8+ Immune Cells in HPV+ Oropharyngeal Squamous Cell Carcinoma
Benjamin Solomon et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck The Active8 Randomized Clinical Trial
Robert L. Ferris et al.
JAMA ONCOLOGY (2018)
Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model
Benjamin Y. Jin et al.
JCI INSIGHT (2018)
HPV 16 E5 oncoprotein is expressed in early stage carcinogenesis and can be a target of immunotherapy
Francesca Paolini et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2017)
Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma
Jennifer D. Moy et al.
EUROPEAN JOURNAL OF CANCER (2017)
Selective blockade of B7-H3 enhances antitumour immune activity by reducing immature myeloid cells in head and neck squamous cell carcinoma
Liang Mao et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2017)
How Standard Is Second-Line Cetuximab in Recurrent or Metastatic Head and Neck Cancer in 2017?
Petr Szturz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
Joshua Bauml et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
hrHPV E5 oncoprotein: immune evasion and related immunotherapies
Antonio Carlos de Freitas et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2017)
Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data
Petr Szturz et al.
ONCOLOGIST (2017)
Analysis of The Cancer Genome Atlas sequencing data reveals novel properties of the human papillomavirus 16 genome in head and neck squamous cell carcinoma
Tara J. Nulton et al.
Oncotarget (2017)
Targeting neoantigens to augment antitumour immunity (vol 17, pg 209, 2017)
Mark Yarchoan et al.
NATURE REVIEWS CANCER (2017)
Management of locally advanced HPV-related oropharyngeal squamous cell carcinoma: where are we?
Stuart E. Samuels et al.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY (2016)
Surgical management of oropharyngeal squamous cell carcinoma: Survival and functional outcomes
Bhavna Kumar et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2016)
Oncologic outcomes of surgically treated early-stage oropharyngeal squamous cell carcinoma
Jason I. Kass et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2016)
CD56-positive lymphocyte infiltration in relation to human papillomavirus association and prognostic significance in oropharyngeal squamous cell carcinoma
Steffen Wagner et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Human Papillomavirus Drives Tumor Development Throughout the Head and Neck: Improved Prognosis Is Associated With an Immune Response Largely Restricted to the Oropharynx
Ankur Chakravarthy et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
Se Jin Im et al.
NATURE (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
David T. Teachey et al.
CANCER DISCOVERY (2016)
Gene expression analysis of TIL rich HPV-driven head and neck tumors reveals a distinct B-cell signature when compared to HPV independent tumors
Oliver Wood et al.
ONCOTARGET (2016)
Incidence of Oropharyngeal Cancer Among Elderly Patients in the United States
Zachary S. Zumsteg et al.
JAMA ONCOLOGY (2016)
The head and neck cancer immune landscape and its immunotherapeutic implications
Rajarsi Mandal et al.
JCI INSIGHT (2016)
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future
Lieping Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer
M. J. Ward et al.
BRITISH JOURNAL OF CANCER (2014)
Randomized Phase III Trial to Test Accelerated Versus Standard Fractionation in Combination With Concurrent Cisplatin for Head and Neck Carcinomas in the Radiation Therapy Oncology Group 0129 Trial: Long-Term Report of Efficacy and Toxicity
Phuc Felix Nguyen-Tan et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
No evidence for active human papillomavirus (HPV) in fields surrounding HPV-positive oropharyngeal tumors
Michelle M. Rietbergen et al.
JOURNAL OF ORAL PATHOLOGY & MEDICINE (2014)
Adjuvant chemoradiation therapy with high-dose versus weekly cisplatin for resected, locally-advanced HPV/p16-positive and negative head and neck squamous cell carcinoma
Jessica L. Geiger et al.
ORAL ONCOLOGY (2014)
Epidemiology of HPV-associated oropharyngeal cancer
Kristen B. Pytynia et al.
ORAL ONCOLOGY (2014)
The role of the PD-L1: PD-1 pathway in squamous cell carcinoma of the head and neck
Dan P. Zandberg et al.
ORAL ONCOLOGY (2014)
Immunologic and metabolic characteristics of HPV-negative and HPV-positive head and neck squamous cell carcinomas are strikingly different
Rosemarie Krupar et al.
VIRCHOWS ARCHIV (2014)
The immune response in HPV+ oropharyngeal cancer
Emma V. King et al.
ONCOIMMUNOLOGY (2014)
A phase I dose escalation trial of MAGE-A3 and HPV-16 specific peptide inurnanotandulatory vaccines in patients with recurrent/inetastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).
Dan Paul Zandberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
Gerald P. Linette et al.
BLOOD (2013)
PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer
Cecile Badoual et al.
CANCER RESEARCH (2013)
Enhanced Radiation Sensitivity in HPV-Positive Head and Neck Cancer
Randall J. Kimple et al.
CANCER RESEARCH (2013)
Low risk of second primary malignancies among never smokers with human papillomavirus-associated index oropharyngeal cancers
Brandon W. Peck et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial
Mariette I. E. van Poelgeest et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Michael S. Lawrence et al.
NATURE (2013)
Promising systemic immunotherapies in head and neck squamous cell carcinoma
Neil Gildener-Leapman et al.
ORAL ONCOLOGY (2013)
Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica
Rolando Herrero et al.
PLOS ONE (2013)
HLA Class I and II Expression in Oropharyngeal Squamous Cell Carcinoma in Relation to Tumor HPV Status and Clinical Outcome
Anders Nasman et al.
PLOS ONE (2013)
The Biology and Life-Cycle of Human Papillomaviruses
John Doorbar et al.
VACCINE (2012)
The determinants of tumour immunogenicity
Thomas Blankenstein et al.
NATURE REVIEWS CANCER (2012)
TRANSORAL LASER MICROSURGERY AS PRIMARY TREATMENT FOR ADVANCED-STAGE OROPHARYNGEAL CANCER: A UNITED STATES MULTICENTER STUDY
Bruce H. Haughey et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2011)
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
Anil K. Chaturvedi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis
Maria R. Parkhurst et al.
MOLECULAR THERAPY (2011)
Intensity-Modulated Chemoradiotherapy Aiming to Reduce Dysphagia in Patients With Oropharyngeal Cancer: Clinical and Functional Results
Felix Y. Feng et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Population-Based Analysis of Oral and Oropharyngeal Carcinoma: Changing Trends of Histopathologic Differentiation, Survival and Patient Demographics
Vikas Mehta et al.
LARYNGOSCOPE (2010)
Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy
Gavin M. Bendle et al.
NATURE MEDICINE (2010)
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
K. Kian Ang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
HPV-16 E5 down-regulates expression of surface HLA class I by CD8 T cells
M. S. Campo et al.
VIROLOGY (2010)
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
J. Paovonen et al.
LANCET (2009)
Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation
Sang Hwan Seo et al.
VACCINE (2009)
HPV Prophylactic Vaccines and the Potential Prevention of Noncervical Cancers in Both Men and Women
Maura L. Gillison et al.
CANCER (2008)
Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows lowtoxicity and robust immunogenicity
Gemma G. Kenter et al.
CLINICAL CANCER RESEARCH (2008)
Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States
Anil K. Chaturvedi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Head and neck cancer: Changing epidemiology, diagnosis, and treatment
Shanthi Marur et al.
MAYO CLINIC PROCEEDINGS (2008)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): An update
Jean-Pierre Pignon et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
JA Bonner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Randomized phase II trial of concomitant chemoradiotherapy using weekly carboplatin or daily low-dose cisplatin for squamous cell carcinoma of the head and neck
A Homma et al.
CANCER JOURNAL (2004)
Evidence for a causal association between human papillomavirus and a subset of head and neck cancers
ML Gillison et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
